Citi reiterated its Sell rating on Athenahealth ATHN after a meeting with the company's management.
In a research report published today, Citi states, "Our meeting... reinforced our belief that in the near term hospitals will resist this painful
change, which could slow the development of the Athena enterprise sales pipeline. A
lack of enterprise sales could lead to disappointing utilization trends and negative
revisions."
At the moment, Citi has a price target of $40 placed on the company's stock. On Friday, the company lost 1.69% of its value to close the week at $42.01.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in